News and information
Adhere to the enterprise spirit of "seeking truth and pragmatism, high quality, unity and harmony, development and innovation", and "integrity and innovation" is the development goal of the enterprise. We will work hand in hand with colleagues and users from all walks of life to seek common development.
Where are you now:
Homepage
/
/
High performance medical devices are key areas in the 13th five year plan

High performance medical devices are key areas in the 13th five year plan

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2015-11-30
  • Views:0

(Summary description)[global medical resources] China's 13th five year plan for the development of pharmaceutical industry and health care has been basically completed and has entered the stage of soliciting opinions. Among them, medical informatization, high-performance medical devices and biomedicine will become the key development areas. These three sub sectors will also become the key support objects of the state during the 13th Five Year Plan period, highlighting investment opportunities.
On March 30, this year, the general office of the State Council issued the national health service system planning outline (2015-2020), pointing out that in the next five years, China will carry out the healthy China cloud service plan, actively apply new technologies such as mobile Internet, Internet of things, cloud computing, wearable devices, etc., to promote health information services and smart medical services that benefit the whole people, and promote health The application of Kangda data will gradually change the service mode and improve the service ability and management level.
At the 2014 China Health conference, Zhang Feng, deputy director of the planning and Information Department of the national health and Family Planning Commission, said that during the "13th five year plan" period, the medical and health industry will be the focus of national informatization development, which has been included in the national key plan for network security and informatization construction.
"Internet plus medicine" will bring about changes and opportunities for the whole big health industry. According to statistics, in 2014, the total amount of venture capital in the field of internet medical care has exceeded US $4.1 billion, an increase of 124% over 2013, involving a total of 258 companies, mainly including big data analysis, medical consumer participation, digital medical equipment, telemedicine, personalized medicine and population health management.
Pharmaceutical e-commerce is also facing significant development opportunities. On May 28, 2014, the State Food and Drug Administration (SFDA) released the "Internet food and drug business supervision and management measures (Draft)", which pointed out that it was planned to open the online sales of prescription drugs, reduce the access threshold for drug sellers, and allow pharmaceutical e-commerce to choose the third-party logistics distribution. Under the "Internet plus" strategy, the approach is expected to come out soon.
"Made in China 2015" released on May 8, this year, pointed out that the biomedical field is the key area to vigorously promote the development of breakthroughs: "to develop new products of chemical drugs, traditional Chinese medicine and biotechnology drugs for major diseases, focusing on new mechanisms and new target chemicals, antibody drugs, new structural protein and peptide drugs, new vaccines, and innovations with outstanding clinical advantages New Chinese medicine and personalized treatment drugs. "
The biomedical industry has a lot of subdivided fields with high technology content and broad prospects. Taking precision medicine as an example, on March 26 this year, the Ministry of science and technology first proposed China's precision medical plan, and pointed out that it would invest 60 billion yuan in this field by 2030.
"Made in China 2025" also proposes to "improve the innovation ability and industrialization level of medical devices, focus on the development of high-performance diagnosis and treatment equipment such as imaging equipment and medical robots, high-value medical consumables such as fully degradable vascular stent, and mobile medical products such as wearable and remote diagnosis and treatment. To achieve breakthroughs and applications of new technologies such as biological 3D printing and induced pluripotent stem cells ".
Due to the late start, low starting point and insufficient research and development, the technical level of medical device industry in China is relatively backward. At present, there are about 15000 medical device manufacturers in China, but up to 90% of the enterprises' income scale is less than 20 million yuan.
The 13th five year plan will be a great opportunity for the development of high performance medical devices in China. For medical device manufacturers, there is a blue ocean ahead.

High performance medical devices are key areas in the 13th five year plan

(Summary description)[global medical resources] China's 13th five year plan for the development of pharmaceutical industry and health care has been basically completed and has entered the stage of soliciting opinions. Among them, medical informatization, high-performance medical devices and biomedicine will become the key development areas. These three sub sectors will also become the key support objects of the state during the 13th Five Year Plan period, highlighting investment opportunities.
On March 30, this year, the general office of the State Council issued the national health service system planning outline (2015-2020), pointing out that in the next five years, China will carry out the healthy China cloud service plan, actively apply new technologies such as mobile Internet, Internet of things, cloud computing, wearable devices, etc., to promote health information services and smart medical services that benefit the whole people, and promote health The application of Kangda data will gradually change the service mode and improve the service ability and management level.
At the 2014 China Health conference, Zhang Feng, deputy director of the planning and Information Department of the national health and Family Planning Commission, said that during the "13th five year plan" period, the medical and health industry will be the focus of national informatization development, which has been included in the national key plan for network security and informatization construction.
"Internet plus medicine" will bring about changes and opportunities for the whole big health industry. According to statistics, in 2014, the total amount of venture capital in the field of internet medical care has exceeded US $4.1 billion, an increase of 124% over 2013, involving a total of 258 companies, mainly including big data analysis, medical consumer participation, digital medical equipment, telemedicine, personalized medicine and population health management.
Pharmaceutical e-commerce is also facing significant development opportunities. On May 28, 2014, the State Food and Drug Administration (SFDA) released the "Internet food and drug business supervision and management measures (Draft)", which pointed out that it was planned to open the online sales of prescription drugs, reduce the access threshold for drug sellers, and allow pharmaceutical e-commerce to choose the third-party logistics distribution. Under the "Internet plus" strategy, the approach is expected to come out soon.
"Made in China 2015" released on May 8, this year, pointed out that the biomedical field is the key area to vigorously promote the development of breakthroughs: "to develop new products of chemical drugs, traditional Chinese medicine and biotechnology drugs for major diseases, focusing on new mechanisms and new target chemicals, antibody drugs, new structural protein and peptide drugs, new vaccines, and innovations with outstanding clinical advantages New Chinese medicine and personalized treatment drugs. "
The biomedical industry has a lot of subdivided fields with high technology content and broad prospects. Taking precision medicine as an example, on March 26 this year, the Ministry of science and technology first proposed China's precision medical plan, and pointed out that it would invest 60 billion yuan in this field by 2030.
"Made in China 2025" also proposes to "improve the innovation ability and industrialization level of medical devices, focus on the development of high-performance diagnosis and treatment equipment such as imaging equipment and medical robots, high-value medical consumables such as fully degradable vascular stent, and mobile medical products such as wearable and remote diagnosis and treatment. To achieve breakthroughs and applications of new technologies such as biological 3D printing and induced pluripotent stem cells ".
Due to the late start, low starting point and insufficient research and development, the technical level of medical device industry in China is relatively backward. At present, there are about 15000 medical device manufacturers in China, but up to 90% of the enterprises' income scale is less than 20 million yuan.
The 13th five year plan will be a great opportunity for the development of high performance medical devices in China. For medical device manufacturers, there is a blue ocean ahead.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2015-11-30
  • Views:0
Information

[global medical resources] China's 13th five year plan for the development of pharmaceutical industry and health care has been basically completed and has entered the stage of soliciting opinions. Among them, medical informatization, high-performance medical devices and biomedicine will become the key development areas. These three sub sectors will also become the key support objects of the state during the 13th Five Year Plan period, highlighting investment opportunities.
On March 30, this year, the general office of the State Council issued the national health service system planning outline (2015-2020), pointing out that in the next five years, China will carry out the healthy China cloud service plan, actively apply new technologies such as mobile Internet, Internet of things, cloud computing, wearable devices, etc., to promote health information services and smart medical services that benefit the whole people, and promote health The application of Kangda data will gradually change the service mode and improve the service ability and management level.
At the 2014 China Health conference, Zhang Feng, deputy director of the planning and Information Department of the national health and Family Planning Commission, said that during the "13th five year plan" period, the medical and health industry will be the focus of national informatization development, which has been included in the national key plan for network security and informatization construction.
"Internet plus medicine" will bring about changes and opportunities for the whole big health industry. According to statistics, in 2014, the total amount of venture capital in the field of internet medical care has exceeded US $4.1 billion, an increase of 124% over 2013, involving a total of 258 companies, mainly including big data analysis, medical consumer participation, digital medical equipment, telemedicine, personalized medicine and population health management.
Pharmaceutical e-commerce is also facing significant development opportunities. On May 28, 2014, the State Food and Drug Administration (SFDA) released the "Internet food and drug business supervision and management measures (Draft)", which pointed out that it was planned to open the online sales of prescription drugs, reduce the access threshold for drug sellers, and allow pharmaceutical e-commerce to choose the third-party logistics distribution. Under the "Internet plus" strategy, the approach is expected to come out soon.
"Made in China 2015" released on May 8, this year, pointed out that the biomedical field is the key area to vigorously promote the development of breakthroughs: "to develop new products of chemical drugs, traditional Chinese medicine and biotechnology drugs for major diseases, focusing on new mechanisms and new target chemicals, antibody drugs, new structural protein and peptide drugs, new vaccines, and innovations with outstanding clinical advantages New Chinese medicine and personalized treatment drugs. "
The biomedical industry has a lot of subdivided fields with high technology content and broad prospects. Taking precision medicine as an example, on March 26 this year, the Ministry of science and technology first proposed China's precision medical plan, and pointed out that it would invest 60 billion yuan in this field by 2030.
"Made in China 2025" also proposes to "improve the innovation ability and industrialization level of medical devices, focus on the development of high-performance diagnosis and treatment equipment such as imaging equipment and medical robots, high-value medical consumables such as fully degradable vascular stent, and mobile medical products such as wearable and remote diagnosis and treatment. To achieve breakthroughs and applications of new technologies such as biological 3D printing and induced pluripotent stem cells ".
Due to the late start, low starting point and insufficient research and development, the technical level of medical device industry in China is relatively backward. At present, there are about 15000 medical device manufacturers in China, but up to 90% of the enterprises' income scale is less than 20 million yuan.
The 13th five year plan will be a great opportunity for the development of high performance medical devices in China. For medical device manufacturers, there is a blue ocean ahead.

Keyword:

Scan the QR code to read on your phone

logo

"Xiangyi" brand has been deeply supported and trusted by the majority of users. Our products are sold all over the country. We strive for survival by quality service and seek development by scientific and technological innovation

Contact information

Company address:
169 Xingguang Avenue, Lidu Town, Jinxian County, Nanchang City, Jiangxi Province

Fixed line:
0791-85638875

mail box:

ncxiangyi@163.com

Contact us

erweima

Copyright: Nanchang Xiangyi Medical Equipment Co., Ltd  Qualification certificate of Internet drug information service: (GAN) - non business-2019-0046    This website supports the visit of IPv4 / IPv6! 翔翊Ganicp13001138 website construction: 300.cn Nanchang